Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
BT’s technology chief has ignited a contentious debate by drawing a parallel between workers threatened by AI and horses replaced by cars.
The global telecommunications firm's chief digital and innovation officer, Harmeen Mehta described the impact of AI on employment as 'part of evolution'.
"I don't know how horses felt when the car was invented, but they didn't complain that they were put out of a job; they didn't go on strike. Some jobs will change, some new ones will be created, and some will no longer be needed," she was quoted as saying in an interview with Raconteur magazine.
The comparison, made in the context of BT's plan to cut up to 55,000 jobs by 2030, has drawn criticism from union leaders who view it as undermining workers' rights.
According to reports, around one-fifth of the company's employees are expected to be replaced by AI. The technology is slated to be predominantly deployed in the customer service division, a move endorsed by outgoing CEO Philip Jansen, who anticipates significant cost savings.
While Mehta downplayed the media's portrayal of AI dangers, emphasising societal changes and job evolution, she urged individuals to retrain to avoid automation-induced unemployment.
She warned, "Every job that exists today won't exist in exactly the same form in the future. The people who reskill themselves will have jobs, at this company or another, while those who don't might not. That is simply part of the evolution of society."
She added, “The media here is creating a level of paranoia that’s going to paralyse this country – it creates more emotional problems for me than I do for myself. I’ve spent the past two years trying to convince my company that human intelligence and artificial intelligence can work together.”
Mehta's remarks triggered accusations that she was questioning workers' intelligence and diminishing their right to strike.
The Communication Workers Union, representing numerous BT employees, defended the right to strike as a hard-won human right, urging serious discussions on AI that respect workers' concerns and ensure reasonable protection.
A spokesperson for BT Group clarified that Mehta used the metaphor to emphasise a point and highlighted the historical pattern of acquiring new skills and creating new jobs during technological shifts. The company expressed its commitment to enabling skill development as human and artificial intelligence collaboratively shape the future workforce.
Having previously served as the chief information officer at the Indian telecom firm Bharti Airtel, Mehta joined BT in 2021 with the goal of revitalising the digital strategy of the former state monopoly.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.